Glycogen synthase kinase‑3β is required for epithelial‑mesenchymal transition and barrier dysfunction in mouse podocytes under high glucose conditions Retraction in /10.3892/mmr.2020.11523

Guo,Jia; Yang,Lili; Qiao,Yingjin; Liu,Zhangsuo

doi:10.3892/mmr.2016.5786

Glycogen synthase kinase‑3β is required for epithelial‑mesenchymal transition and barrier dysfunction in mouse podocytes under high glucose conditions

Retraction in: /10.3892/mmr.2020.11523

Authors:
- Jia Guo
- Lili Yang
- Yingjin Qiao
- Zhangsuo Liu
View Affiliations

Affiliations: Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: September 26, 2016 https://doi.org/10.3892/mmr.2016.5786
Pages: 4091-4098
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial-mesenchymal transition (EMT) is important for diabetic nephropathy (DN). Podocytes are specialized epithelial cells, which form a major component of the glomerular filtration barrier. Podocyte damage has been suggested to be the primary mechanism behind the albuminuria associated with DN. The present study aimed to determine the function of glycogen synthase kinase (GSK)‑3β in EMT and barrier dysfunction of mouse podocytes exposed to high glucose (HG) conditions. Matured and differentiated podocytes were treated with normal glucose (NG), HG or NG + mannitol. Podocytes were also transfected with a small interfering RNA (siRNA) against GSK‑3β or a scrambled siRNA, or were treated with lithium chloride (LiCl), a GSK‑3β inhibitor, under NG or HG conditions. The expression levels of the epithelial cell markers, nephrin and podocin, and the myofibroblast cell markers, α‑smooth muscle actin (SMA) and fibronectin, in podocytes by western blot analysis and immunofluorescence staining, respectively. The monolayer barrier function was assessed by albumin inflow. The phosphorylation and activity levels of GSK‑3β were also quantified. It was observed that HG promotes EMT in podocytes, due to the increased levels of podocin and nephrin expression and the reduced α‑SMA and fibronectin expression levels. HG also induced barrier dysfunction and increased the expression level of total GSK‑3β, Try216‑phosphorylated‑GSK‑3β and the GSK‑3β activity in podocytes. Transfection of GSK‑3β siRNA or treatment with LiCl reversed the HG‑induced EMT and barrier dysfunction in podocytes. In conclusion, the present study determined that GSK‑3β is required for EMT and barrier dysfunction in podocytes under HG conditions; therefore, GSK‑3β may be a novel target for the treatment of DN.

View Figures

View References

1	Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Johansen K, Kasiske B, Kutner N, Liu J, St Peter W, et al: United States renal data system 2011 annual data report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 59(1 Suppl 1). (A7): e1–e420. 2012.
2	Wiggins RC: The spectrum of podocytopathies: A unifying view of glomerular diseases. Kidney Int. 71:1205–1214. 2007. View Article : Google Scholar : PubMed/NCBI
3	Juarez G Fernandez, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, et al: Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: A randomized trial. Am J Kidney Dis. 61:211–218. 2013. View Article : Google Scholar : PubMed/NCBI
4	Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z and Shahinfar S: RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:861–869. 2001. View Article : Google Scholar : PubMed/NCBI
5	Soda K, Balkin DM, Ferguson SM, Paradise S, Milosevic I, Giovedi S, Volpicelli-Daley L, Tian X, Wu Y, Ma H, et al: Role of dynamin, synaptojanin, and endophilin in podocyte foot processes. J Clin Invest. 122:4401–4411. 2012. View Article : Google Scholar : PubMed/NCBI
6	Li Y, Kang YS, Dai C, Kiss LP, Wen X and Liu Y: Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol. 172:299–308. 2008. View Article : Google Scholar : PubMed/NCBI
7	Jope RS, Yuskaitis CJ and Beurel E: Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics. Neurochem Res. 32:577–595. 2007. View Article : Google Scholar : PubMed/NCBI
8	Campa VM and Kypta RM: Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells. Biol Direct. 6:42011. View Article : Google Scholar : PubMed/NCBI
9	Liu Y: New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol. 21:212–222. 2010. View Article : Google Scholar : PubMed/NCBI
10	Bachelder RE, Yoon SO, Franci C, de Herreros AG and Mercurio AM: Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: Implications for the epithelial-mesenchymal transition. J Cell Biol. 168:29–33. 2005. View Article : Google Scholar : PubMed/NCBI
11	Guo J, Xia N, Yang L, Zhou S, Zhang Q, Qiao Y and Liu Z: GSK-3β and vitamin D receptor are involved in β-catenin and snail signaling in high glucose-induced epithelial-mesenchymal transition of mouse podocytes. Cell Physiol Biochem. 33:1087–1096. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sharma K, Deelman L, Madesh M, Kurz B, Ciccone E, Siva S, Hu T, Zhu Y, Wang L, Henning R, et al: Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells. Am J Physiol Renal Physiol. 285:F1258–F1270. 2003. View Article : Google Scholar : PubMed/NCBI
13	McGowan TA, Madesh M, Zhu Y, Wang L, Russo M, Deelman L, Henning R, Joseph S, Hajnoczky G and Sharma K: TGF-beta-induced Ca(2+) influx involves the type III IP(3) receptor and regulates actin cytoskeleton. Am J Physiol Renal Physiol. 282:F910–F920. 2002. View Article : Google Scholar : PubMed/NCBI
14	Rico M, Mukherjee A, Konieczkowski M, Bruggeman LA, Miller RT, Khan S, Schelling JR and Sedor JR: WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. Am J Physiol Renal Physiol. 289:F431–F441. 2005. View Article : Google Scholar : PubMed/NCBI
15	Leeuwis JW, Nguyen TQ, Dendooven A, Kok RJ and Goldschmeding R: Targeting podocyte-associated diseases. Adv Drug Del Rev. 62:1325–1336. 2010. View Article : Google Scholar
16	Dai C, Stolz DB, Bastacky SI, St-Arnaud R, Wu C, Dedhar S and Liu Y: Essential role of integrin-linked kinase in podocyte biology: Bridging the integrin and slit diaphragm signaling. J Am Soc Nephrolo. 17:2164–2175. 2006. View Article : Google Scholar
17	El-Aouni C, Herbach N, Blattner SM, Henger A, Rastaldi MP, Jarad G, Miner JH, Moeller MJ, St-Arnaud R, Dedhar S, et al: Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. J Am Soc Nephrolo. 17:1334–1344. 2006. View Article : Google Scholar
18	Lee J and Kim MS: The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Res Clin Pract. 77:(Suppl 1). S49–S57. 2007. View Article : Google Scholar : PubMed/NCBI
19	Marshall SM: The podocyte: A major player in the development of diabetic nephropathy? Horm Metab Res. 37:(Suppl 1). S9–S16. 2005. View Article : Google Scholar
20	Billing H, Müller D, Ruf R, Lichtenberger A, Hildebrandt F, August C, Querfeld U and Haffner D: NPHS2 mutation associated with recurrence of proteinuria after transplantation. Pediatr Nephrol. 19:561–564. 2004. View Article : Google Scholar : PubMed/NCBI
21	Hautmann MB, Adam PJ and Owens GK: Similarities and differences in smooth muscle alpha-actin induction by TGF-beta in smooth muscle versus non-smooth muscle cells. Arterioscler Thromb Vasc Biol. 19:2049–2058. 1999. View Article : Google Scholar : PubMed/NCBI
22	Lv Z, Hu M, Zhen J, Lin J, Wang Q and Wang R: Rac1/PAK1 signaling promotes epithelial-mesenchymal transition of podocytes in vitro via triggering β-catenin transcriptional activity under high glucose conditions. Int J Biochem Cell Biol. 45:255–264. 2013. View Article : Google Scholar : PubMed/NCBI
23	Chen T, Zheng LY, Xiao W, Gui D, Wang X and Wang N: Emodin ameliorates high glucose induced-podocyte epithelial-mesenchymal transition in-vitro and in-vivo. Cell Physiol Biochem. 35:1425–1436. 2015. View Article : Google Scholar : PubMed/NCBI
24	Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y and Minamoto T: Deregulated GSK3beta activity in colorectal cancer: Its association with tumor cell survival and proliferation. Biochem Biophysl Res Commun. 334:1365–1373. 2005. View Article : Google Scholar
25	Lin CL, Wang JY, Huang YT, Kuo YH, Surendran K and Wang FS: Wnt/beta-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol. 17:2812–2820. 2006. View Article : Google Scholar : PubMed/NCBI
26	Paeng J, Chang JH, Lee SH, Nam BY, Kang HY, Kim S, Oh HJ, Park JT, Han SH, Yoo TH, et al: Enhanced glycogen synthase kinase-3β activity mediates podocyte apoptosis under diabetic conditions. Apoptosis. 19:1678–1690. 2014. View Article : Google Scholar : PubMed/NCBI
27	Shang G, Tang X, Gao P, Guo F, Liu H, Zhao Z, Chen Q, Jiang T, Zhang N and Li H: Sulforaphane attenuation of experimental diabetic nephropathy involves GSK-3 beta/Fyn/Nrf2 signaling pathway. J Nutr Biochem. 26:596–606. 2015. View Article : Google Scholar : PubMed/NCBI
28	Mariappan MM, Prasad S, D'Silva K, Cedillo E, Sataranatarajan K, Barnes JL, Choudhury GG and Kasinath BS: Activation of glycogen synthase kinase 3β ameliorates diabetes-induced kidney injury. J Biol Chem. 289:35363–35375. 2014. View Article : Google Scholar : PubMed/NCBI